Overview of
The Karen Cheng Advocacy Program  

Karen was diagnosed with Stage IV lung cancer with EGFR mutation (exon 20 insertions) in August 2017 She completed many treatments including TT, chemotherapy, surgery, and immunotherapy. in July of 2019, Karen joined a clinical trial in Shanghai and was an active volunteer at Cancerinformation for more than four years.

Karen with members of Cancerinformation
Karen with her friends at Cancerinfo

Information provided by Cancerinformation.com.hk

  • Cancerinformation.com.hk Limited (CI), is an integrated digital platform with over 50,000 followers that provides insightful information and cancer patient care services in Hong Kong. We aim at providing positive messages, up-to-date health education, and emotional support to both cancer patients, as well as their families and caregivers.
  • Cancerinformation.com.hk Charity Foundation (CICF), is an independent charity registered in Hong Kong with tax exemption under section 88 of the Inland Revenue Ordinance. Our mission is to provide support to those living with cancer, empower cancer patients and caregivers in different aspects, build survivor community, provide patient assistance programs, raise awareness, redefine the quality of life, and advocate for survivorship. We believe that through the exchange of ideas we can drive positive change.

Because of our Generous Supporters, ICAN patients involved in
The Karen Cheng Advocacy Program
have access to the following information services:

  • A review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, diet, lifestyle and risk factors, current condition as well as any comorbid factors; and complete review of symptoms prior to presentation.
  • Referrals, at the patient contact's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, and additional specialists relevant to the patient's ongoing care.
  • Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
  • Referrals to cancer-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
  • Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from other treatment modalities.
  • Discussion of the interaction of diet and cancer chemotherapy drugs based on recent studies.
  • Delineation of the symptoms about which the patient should alert his/her oncologist.
  • Discussion of relevant imaging technology.
  • Discussion of pain management issues and treatment options that can be addressed with the patient's medical team.
  • Explanation of the recommendations given or not given by the patient's physicians; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
  • Review of the relevant radiotherapy/interventional radiology options which the patient contact, in turn, may discuss with his/her medical team.
  • Review the patient’s genomics, proteomics, transcriptomics, and immune cell studies to best prioritize clinical trial options and sequencing of therapies.
  • Analysis of relevant cancer clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
  • Review of relevant cancer-specific drugs in the anticancer pipeline.
  • Review of all relevant and complementary and alternative medicine ("CAM") avenues.
  • Review of the merits of filing a "Single Patient IND for Compassionate or Emergency Use" for a specific experimental cancer drug, if relevant to the patient's situation.
  • Exploration of options that might reduce travel costs for the patient contact, such as Corporate Angels Network, as well as ICAN supporters who have volunteered to host a clinical trials patient in a particular city.

The Karen Cheng Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.

ICAN is currently working on The Karen Cheng Advocacy Program . We are working to put together a Family and Friends Advisory Council for the The Karen Cheng Advocacy Program . If interested, please email us at Karen.Cheng.Program@askican.org.

If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at Karen.Cheng.Program@askican.org.


Guidestar Platinum Seal of Transparency 2021


Federal Tax I.D.: EIN 86-0818253